previously demonstrated an association between stillbirth and maternal marijuana use as defined by the presence of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid in the umbilical cord homogenate. However, the relationship between marijuana use and perinatal complications in live births is uncertain. OBJECTIVE: Our aim was to examine if maternal marijuana use is associated with increased odds of adverse pregnancy outcomes and neonatal morbidity among live-born controls in the Stillbirth Collaborative Research Network cohort. STUDY DESIGN: We conducted a secondary analysis of singleton, live-born controls in the Stillbirth Collaborative Research Network data set. Marijuana use was measured by self-report and/or the presence of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid in umbilical cord homogenate. Tobacco use was measured by self-report and/or presence of any cotinine in maternal serum. Adverse pregnancy outcome was a composite of small for gestational age, spontaneous preterm birth resulting from preterm labor with or without intact membranes, and hypertensive disorders of pregnancy. Neonatal morbidity included neonatal intensive care unit admission and composite neonatal morbidity (pulmonary morbidity, necrotizing enterocolitis, seizures, retinopathy of prematurity, infection morbidity, anemia requiring blood transfusion, neonatal surgery, hyperbilirubinemia, neurological morbidity, or death prior to hospital discharge). Effect of maternal marijuana use on the probability of an adverse outcome was estimated using weighted methodology to account for oversampling in the original study. 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid cord homogenate analysis was performed in the subset of women for whom biospecimens were available. Comparisons using logistic modeling, c 2 , and t tests were weighted to account for oversampling of preterm births and non-Hispanic blacks. Results are reported as weighted percent and unweighted frequencies.
Introduction
Legalization of marijuana in the United States has resulted in a resurgence of interest in its health effects. More women now report using marijuana either recreationally or to treat nausea and vomiting of pregnancy. 1 From 2002 through 2014, past-month use among pregnant women increased from 2.4-3.9%. 2 With increasing use, there is an urgent need for high-quality data regarding the health effects of marijuana in pregnancy to appropriately educate women and health care providers.
Previous studies on the association between marijuana use and perinatal outcomes have yielded mixed results, [3] [4] [5] [6] [7] [8] likely due to incomplete ascertainment of exposure without quantification of marijuana use, and without corroboration of use with biological sampling. 3 The Eunice Kennedy Shriver National Institute of Child Health and Human Development Stillbirth Collaborative Research Network (SCRN) recently demonstrated an association between maternal marijuana use and stillbirth. 9 The SCRN utilized umbilical cord homogenate assays, allowing for detection of use from the second trimester onward. Our objective was to examine if maternal marijuana use is associated with increased odds of adverse pregnancy outcomes (small for gestational age [SGA] , spontaneous preterm birth [SPTB] , and hypertensive disorders of 
Materials and Methods
This was a SCRN secondary data analysis. The original study enrolled stillbirths in a geographically and racially diverse population. Live-born controls between 20-31 weeks were oversampled at the time of the original study to provide numbers similar to those of stillbirths during each gestational week, and were therefore oversampled for adverse pregnancy outcomes resulting in preterm births. Prospective enrollment occurred from March 2006 through September 2008. Details regarding the methodology of the original study and selection of the live-born controls were previously published. 10 The study was approved by the institutional review boards of each participating institution.
For this analysis, all women with nonanomalous singleton live births !24 weeks were considered for inclusion. Women with missing obstetrical history data and/or drug or tobacco use were excluded. The adverse pregnancy outcome was a composite of SGA, SPTB, and HTN. SGA was defined as a birthweight <10th percentile for gestational age.
11 SPTB was defined as a preterm delivery (<37 weeks) resulting from spontaneous preterm labor with or without intact membranes. HTN included gestational hypertension and preeclampsia. Standard definitions of HTN were utilized. 10 Women without data available for any component of the composite adverse pregnancy outcome were excluded.
Neonatal morbidity outcomes included NICU admission or a composite neonatal morbidity defined as any evidence of neonatal pulmonary morbidity (respiratory distress syndrome, persistent pulmonary hypertension, bronchopulmonary dysplasia, pulmonary hypoplasia), necrotizing enterocolitis, seizures, retinopathy of prematurity, infection morbidity (sepsiseclinical or blood culture confirmed, pneumonia, or bacterial meningitis), anemia requiring blood transfusion, neonatal surgery, hyperbilirubinemia, neurological morbidity (any grade of intraventricular hemorrhage or periventricular leukomalacia), or neonatal death prior to discharge. Standard neonatal morbidity definitions were used. 12 Our primary exposure was maternal marijuana use as measured by self-report and/or the presence of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in umbilical cord homogenate. Self-report of any drug use was obtained through a standardized maternal interview within 4 weeks of the delivery hospitalization and any use during pregnancy was obtained via chart abstraction by the research team.
Drug assays of umbilical cord segments occurred at US Drug Testing Laboratories Inc (USDTL). A 3.5-g segment of umbilical cord was drained of blood, rinsed with saline, and dried. Specimens were frozen at e80 C in a 15-mL vial until the time of drug assay (THC-COOH is stable when stored at temperatures <e20 C). 13 The cord was homogenized and drug assays were performed initially by enzyme-linked immunosorbent analysis for cannabinoids, amphetamine, methamphetamine, cocaine, meperidine, and hydrocodone. Positive results by enzyme-linked immunosorbent analysis were confirmed using mass spectrometry. 13 The mass spectrometry methodology was two-dimensional gas chromotography coupled to mass spectrometry (GC-GC/MS) with Deans switch methodology and negative chemical ionization detection mass spectrometry for THC-COOH similar to that described for USDTL hair assays.
14 In comparison to meconium drug assays, umbilical cord homogenate sampling detects maternal marijuana use in term infants from as early as 20 weeks' gestation.
13, 15 The placenta and umbilical cord were not always collected at delivery so not all participants had samples available. Cord collection and processing details were previously published. 16 For this analysis, illicit drug use was defined as reported use of heroin; cocaine (street name "crack"); amphetamines including crystal methamphetamine; inhalants; 3,4-methylenedioxymethamphetamine (street name "ecstasy"); hallucinogens; or a drug assay positive for 1 of these substances.
Tobacco use is an important confounder, and was measured by selfreport and/or detectable maternal serum cotinine. Self-reported tobacco was defined as reporting !1 cigarette every day in any trimester or any tobacco use after diagnosis of pregnancy. Serum samples were collected at delivery admission. Specimens were centrifuged at 1300g for 15 minutes, then aliquoted and stored at e80 C until the time of assay. Cotinine assays were performed using liquid chromotography. 17 For our primary analysis, any cotinine in the maternal serum was considered indicative of tobacco use. In sensitivity analysis, cotinine was defined with 3 levels of exposure: none (undetectable), passive (<3 ng/mL), and presumed (!3 ng/mL) smoker based on previously established cut-offs. 9 We used c 2 and t test as appropriate to compare demographic characteristics between women who used marijuana to nonusers. Groups were also compared for frequencies of the adverse composite outcome and each individual component. All calculated comparisons utilized weightings that reflected the original study design of oversampling at early gestational ages and for non-Hispanic black race. The methodology for weighting the sample has been published previously. 10 The effect of maternal marijuana use on the probability of the composite adverse pregnancy outcome was estimated using a logistic regression model. Race, obstetrical history (categorized as nulliparous, parous with history of term births only, parous with history of preterm birth <37 weeks), tobacco use, illicit drug use, and body mass index (BMI) were determined to be clinically important covariates and were considered in multivariable modeling. In addition, socioeconomic factors that differed between groups in univariable analysis and the interaction between marijuana and tobacco were considered for inclusion. A final model was selected through sequential, backwards elimination of covariates with P > .05.
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A second regression model of the composite adverse pregnancy outcome was estimated among the subset of women for whom biospecimens were available.
The effect of maternal marijuana use on the probability of the composite neonatal morbidity was estimated using a logistic regression model. Race, tobacco use, illicit drug use, and BMI were determined to be clinically important covariates and were considered in multivariable modeling. In addition, socioeconomic factors that differed between groups in univariable analysis and the interaction between marijuana and tobacco were considered for inclusion. A final model was selected through sequential, backwards All results are reported as weighted percentages.
WIC, Special Supplemental Nutrition Program for Women, Infants, and Children.
a Self-reported illicit drug use includes cocaine (street name "crack"), heroin, amphetamines including crystal methamphetamine, inhalants, and 3,4-methylenedioxymethamphetamine (street name "ecstasy")ecord homogenate results on subset of n ¼ 30 women who use marijuana, and n ¼ 867 nonusers, includes all illicit drugs listed aboveematernal serum cotinine results were available on subset of n ¼ 1313 women. A second model of composite neonatal morbidity among the subset of women with biospecimens was not estimated given the low frequency of neonatal morbidity among women with biospecimens available. P < .05 was considered statistically significant. All analyses were completed in SAS 9.4 (SAS Institute, Carey, NC) (specifically proc SurveyLogistic for modeling), with graphics created using Graphpad Prism v6.03 (GraphPad Software, San Diego, CA).
Results
There were 1996 live-born controls in the data set. In all, 386 women were excluded with some women meeting more than one exclusion criterion (n ¼ 77 missing component of adverse pregnancy outcome, n ¼ 63 missing BMI, n ¼ 125 multiple gestation, n ¼ 74 missing drug use variable, n ¼ 137 births <24 weeks gestational age, and n ¼ 14 congenital anomalies (Table 1) .
The composite adverse pregnancy outcome, and each component of the composite outcome, was present more frequently in women with marijuana use compared to nonusers (Table 2) . However, none of these differences were significant in univariable comparisons.
In the primary model, any use of marijuana was included as the exposure (either self-report or THC-COOH by biological sampling). After adjustment for race, obstetrical history, and BMI, the association of marijuana use with the composite adverse pregnancy outcome was not significant (adjusted odds ratio [aOR], 1.29; 95% CI, 0.57e2.97), but that of tobacco use was (aOR, 1.66; 95% CI, 1.10e2.49) (Figure 1 ). The interaction between tobacco and marijuana use was nonsignificant (P > .4).
In a second model, among women with umbilical cord homogenate and serum cotinine data (n ¼ 765), the association of marijuana use with the composite adverse pregnancy outcome remained nonsignificant (aOR, 1.02; 95% CI, 0.18e5.66), while the effect of tobacco use was larger in magnitude (aOR, 2.50; 95% CI, 1.32e4.75) in comparison to the primary model ( Figure 1 ). Illicit drug use was not associated with adverse outcomes in either model. Since 59 women had cotinine levels <3 ng/mL and this may reflect only passive exposure, a sensitivity analysis with 3 categories of cotinine levels was performed. The odds Effect of maternal marijuana use on adverse pregnancy outcomes Multivariable modeling to estimate association between maternal marijuana use and composite adverse pregnancy outcome (spontaneous preterm birth, hypertensive disorders of pregnancy, and/ or small for gestational age) while adjusting for tobacco use and other sociodemographic factors. Education; interaction between tobacco and marijuana; illicit drug use; and participation in Special Supplemental Nutrition Program for Women, Infants, and Children were eliminated from model as nonsignificant covariates.
BMI, body mass index; CI, confidence interval; THC-COOH, tetrahydrocannabinol. Women with any marijuana use (self-report or THC-COOH in cord homogenate) were compared to nonusers for neonatal morbidity. Groups were similar with regard to NICU admission and gestational age at delivery (38.4 AE 0.37 weeks for users vs 38.8 AE 0.05 weeks for nonusers; P ¼ .277). However, composite neonatal morbidity or death was more frequent among neonates of mothers who used marijuana (Table 3) . Upon further exploration of the components of composite neonatal morbidity, infection morbidity and neurological morbidity were significantly more frequent among women with marijuana use (Table 3) . After adjustment for race and illicit drug use, marijuana use was associated with neonatal morbidity (aOR, 3.11; 95% CI, 1.40e6.91), and tobacco use was not (aOR, 1.23; 95% CI, 0.66e2.30) (Figure 2) . The interaction between tobacco and marijuana use was nonsignificant (P > .2).
Comment
Maternal marijuana use (self-report or presence of THC-COOH in the umbilical cord homogenate) was not associated with a composite adverse pregnancy outcome of SGA, SPTB, and HTN independent of tobacco use, but was associated with neonatal morbidity.
High-quality data regarding the effects of marijuana use in pregnancy are wanting owing to a lack of systematic investigation. The majority of existing studies did not distinguish between medically indicated preterm birth and SPTB; however, 2 recent studies demonstrate an increased risk of SPTB with marijuana use. 18, 19 In our study, women who used marijuana had SPTB (preterm labor with or without intact membranes) twice as frequently as those who did not use marijuana (13% vs 6%), although this was not statistically significant. Separation of medically indicated preterm birth from SPTB will be important in future studies.
Most prior studies focused on the association between maternal marijuana use and fetal growth. We found no association between marijuana use and SGA. A meta-analysis by English et al 4 published in 1997 found no association between marijuana exposure and low birthweight (pooled OR, 1.09; 95% CI, 0.94e1.27). Nine of the 10 studies in the meta-analysis used only self-report of marijuana use. Zuckerman et al 20 found an association between marijuana use and lower birthweight, and suggested that the lack of observed association in other studies may be a result of reliance on self-report.
In contrast, there are few data regarding the effect of marijuana on HTN. We found no increase in HTN in women who used marijuana (14 vs 9%). There is limited evidence to evaluate whether marijuana use is associated with pregnancy complications for the mother. 8 Future work will need to emphasize timing of exposure and biologic plausibility for outcomes of interest.
A recent systematic review and metaanalysis concluded that marijuana use was not associated with adverse neonatal outcomes defined as birthweight <2500 g or preterm delivery <37 weeks. 7 Secondary outcomes that overlapped with Composite neonatal morbidity includes indented list presented in remaining rows of table.
All results are reported as weighted percentages, P value from weighted c 2 .
Composite neonatal morbidity endpoint was defined by "any yes" or "all no," as such some item nonresponse is present for individual components. 
SMFM Papers
ajog.org our studied outcomes were level !II nursery admission, SGA, and perinatal death. Notably, none of the neonatal morbidity outcomes included in our composite were investigated as part of this meta-analysis. The difference between our findings and the published meta-analysis may simply reflect the addition of a number of other neonatal morbidities, including preterm morbidities, in our analysis.
Data regarding preterm morbidity and marijuana use are limited. We found increased neurologic morbidity in neonates exposed to marijuana. Viteri et al 21 found an association between stillbirth and/or cerebral palsy among preterm neonates exposed to illicit drugs, while another secondary analysis found no association between marijuana use and neurologic morbidity in preterm neonates. 22 Further work is needed to confirm this association, and to determine whether marijuana use causes neonatal morbidity independent of preterm birth.
The observed increase in neonatal infection morbidity has biologic plausibility. There are existing animal data demonstrating changes in the immune response related to cannabis exposure with evidence of immune suppression and T-cell dysfunction. [23] [24] [25] [26] These changes may result from epigenetic modifications, which could result in long-term changes to the immunologic response following in utero exposure. 27 While we found an association between neonatal morbidity and marijuana use, we did not find a significant difference in rates of NICU admission (Table 3 ). This may simply be a reflection of the need for a larger sample size. The higher rates of NICU admission compared to morbidity were predominantly a result of admissions for ruleout infection, or mild respiratory distress including desaturations following delivery. The rates of NICU admission in our study are similar to those published by Warshak et al, 28 who identified an increased rate of NICU admission among women (N ¼ 6468) who use cannabis compared to nonusers (17.2 vs 12.5%). A recent systematic review and meta-analysis also noted an increase in NICU admission among neonates exposed to cannabis in utero (pooled OR, 2.02; 95% CI, 1.27e3.21). 6 The observed increased risk of NICU admission in these and other studies, 29 coupled with our finding of increased neonatal morbidity, emphasizes the need to rigorously evaluate neonatal morbidity in this population.
In our cohort, the agreement between self-reported maternal marijuana use and biological sampling was poor. These findings are consistent with a study from Shiono et al 30 in 1995 in which 69% of women with a positive maternal serum screen for THC-COOH denied use in a structured interview. The unwillingness of pregnant women to disclose use may reflect social desirability bias, or concern for the ramifications of reporting. Regardless of the rationale, marijuana use is underreported, which speaks to the importance of incorporating biologic sampling into future protocols for ascertainment of exposure.
The importance of biological sampling is also emphasized in the National Academies Press publication of the state of the evidence for health effects of cannabis and recommendations for research. 8 Umbilical cord homogenate sampling has promise for quantification of use as it performs similarly to meconium testing, and is thought to be a marker of use from the second trimester onward. 15 This is in contrast to urine or plasma, which reflect use for days to weeks depending on the chronicity of use. However, there are limited data as to how long THC-COOH is detectable in the cord homogenate (thought to be as early as 20 weeks in term infants). 13 In addition, despite validation of umbilical cord homogenate testing in other studies, the poor agreement observed may reflect low sensitivity of the assay for THC-COOH in women who are less frequent users. Given that the umbilical cord essentially acts as a reservoir for drug metabolites, future work should focus on whether maternal marijuana use can be quantified through sampling of the umbilical cord alone.
Strengths and limitations
Our study had several limitations. The most important are the infrequency of Effect of maternal marijuana use on neonatal morbidity Multivariable modeling to estimate association between maternal marijuana use and composite neonatal morbidity while adjusting for tobacco use and other sociodemographic factors. Education; participation in Special Supplemental Nutrition Program for Women, Infants, and Children; body mass index; and interaction between tobacco and marijuana were eliminated from model as nonsignificant covariates. ajog.org SMFM Papers marijuana use in this cohort, and the lack of available data regarding individual use patterns. The observed lack of an association between marijuana use and the primary composite adverse outcome may be attributable to insufficient sample size. With a fixed sample size of n ¼ 48 women who use marijuana and n ¼ 1562 nonusers, we could detect the observed difference of 10% if the prevalence rates of the adverse outcome were lower (ie, 15% vs 5% rather than 31% vs 21%) using a 2-sided t test with a significance level of .05 and 80% power. However, with the high proportion of adverse outcomes, we did not have sufficient power to detect this difference.
There was poor agreement between self-reported marijuana use and objective documentation, limiting the value of self-reported data. Also, some cases (44%), as part of the parent study design, had no biospecimen data available, potentially introducing bias. Finally, we do not have long-term follow-up data on the neonates to assess for childhood outcomes.
A major strength of the study was the use of biological sampling from umbilical cord homogenate to objectively assess maternal marijuana use. In addition, we had rigorous data collection by trained personnel; population-based sampling resulting in a racially, ethnically, and geographically diverse population; and a large number of cases with adverse pregnancy outcomes.
Conclusions
Further study of the association between maternal marijuana use and adverse perinatal outcomes with biological sampling may help to educate women and providers about the anticipated effects of maternal marijuana use. n
